Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 1
1999 1
2001 2
2002 5
2003 2
2004 5
2005 5
2006 9
2007 9
2008 2
2009 7
2010 5
2011 5
2012 4
2013 2
2014 7
2015 4
2016 3
2017 4
2018 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17674445

82 results

Results by year

Filters applied: . Clear all
Page 1
Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.
Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J; Scandinavian Prostate Cancer Group. Iversen P, et al. Scand J Urol Nephrol. 2006;40(6):441-52. doi: 10.1080/00365590601017329. Scand J Urol Nephrol. 2006. PMID: 17130095 Clinical Trial.
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group. See WA, et al. J Urol. 2002 Aug;168(2):429-35. J Urol. 2002. PMID: 12131282 Clinical Trial.
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Iversen P, et al. Urology. 2004 May;63(5):928-33. doi: 10.1016/j.urology.2004.02.011. Urology. 2004. PMID: 15134983 Clinical Trial.
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group. Iversen P, et al. J Urol. 2004 Nov;172(5 Pt 1):1871-6. doi: 10.1097/01.ju.0000139719.99825.54. J Urol. 2004. PMID: 15540741 Clinical Trial.
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K; Scandinavian Prostatic Cancer Group (SPCG). Iversen P, et al. Eur Urol. 2002 Sep;42(3):204-11. doi: 10.1016/s0302-2838(02)00311-1. Eur Urol. 2002. PMID: 12234503 Clinical Trial.
82 results